Combined Interval Cytoreductive Surgery and Carboplatin-Based Hyperthermic Intraperitoneal Chemotherapy in Advanced Primary High-Grade Serous Ovarian Cancer
Authors:
- Claudèle BraultCBClaudèle Brault
- Alexandre Brind’amourABAlexandre Brind’amour
- Lara de GuerkeLGLara de Guerke
- Marie-Hélène AuclairMAMarie-Hélène Auclair
- Lucas SiderisLucas Sideris
- Pierre DubéPDPierre Dubé
- Mikaël SoucisseMSMikaël Soucisse
- Jean-François TremblayJTJean-François Tremblay
- Laurence BernardLBLaurence Bernard
- Sabrina PiedimonteSPSabrina Piedimonte
- Suzanne FortinSFSuzanne Fortin
Open Access
- 1 December 2023
- journal article
- research article
- Published by MDPI AG in Current Oncology
- Vol. 30 (12) , 10272-10282
Abstract
Combining interval cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) improves survival in advanced epithelial ovarian carcinoma (EOC). Although limited, growing evidence regarding carboplatin-based HIPEC highlights its potential. This retrospective study included all patients with advanced primary high-grade serous ovarian cancer who underwent interval CRS combined with carboplatin-based HIPEC at our Canadian tertiary care center between 2014 and 2020. We identified 40 patients with a median age of 61 years. The median peritoneal cancer index was 13 and complete cytoreduction was achieved in 38 patients (95%). Median hospital stay was 13 days and there were four admissions to the intensive care unit (10%) and six readmissions (15%). Severe adverse events occurred in eight patients (20%) and there was no perioperative death. Recurrence was seen in 33 patients (82%) with a median DFS of 18.0 months and a median overall survival of 36.4 months. Multivariate analyses showed that age, peritoneal cancer index, completeness of cytoreduction, occurrence of severe complications, and bowel resection did not significantly impact DFS or OS in our cohort. Interval CRS combined with carboplatin-based HIPEC for advanced primary EOC is associated with acceptable morbidity and oncological outcomes. Larger studies are required to determine the long-term outcomes.Keywords
This publication has 29 references indexed in Scilit:
- Hyperthermic intraperitoneal chemotherapy (HIPEC) and cytoreductive surgery (CRS) in ovarian cancer: A systematic review and meta-analysisEuropean Journal of Surgical Oncology, 2015
- HIPEC ROC I: A phase i study of cisplatin administered as hyperthermic intraoperative intraperitoneal chemoperfusion followed by postoperative intravenous platinum‐based chemotherapy in patients with platinum‐sensitive recurrent epithelial ovarian cancerInternational Journal of Cancer, 2014
- Peritoneal carcinomatosis treated with cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for advanced ovarian carcinoma: A French multicentre retrospective cohort study of 566 patientsEuropean Journal of Surgical Oncology, 2013
- Hyperthermic intraperitoneal chemotherapy with carboplatin for optimally-cytoreduced, recurrent, platinum-sensitive ovarian carcinoma: A pilot studyGynecologic Oncology, 2013
- Cytoreductive surgery and modified heated intraoperative intraperitoneal chemotherapy (HIPEC) for advanced and recurrent ovarian cancer – 12-year single center experienceEuropean Journal of Surgical Oncology, 2009
- The Clavien-Dindo Classification of Surgical ComplicationsAnnals of Surgery, 2009
- Intraperitoneal Cisplatin and Paclitaxel in Ovarian CancerNew England Journal of Medicine, 2006
- Identification of Prognostic Factors in Advanced Epithelial Ovarian CarcinomaGynecologic Oncology, 2001
- A pilot phase I trial of continuous hyperthermic peritoneal perfusion with high-dose carboplatin as primary treatment of patients with small-volume residual ovarian cancerCancer Chemotherapy and Pharmacology, 1999
- Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis1996